

# ACIP Meningococcal Vaccines Work Group Introduction

Katherine Poehling, MD, MPH Work Group Chair

February 23, 2023

#### Meningococcal Vaccines Work Group

- ACIP Members
  - Katherine Poehling (Chair)
  - Lynn Bahta
  - Jamie Loehr
- Ex Officio Members
  - Margaret Bash (FDA)
  - Mark Connelly (FDA)
  - Francisco Leyva (NIH)
- CDC Lead
  - Sam Crowe (DBD/NCIRD)
- Liaisons and Consultants
  - Amra Resic (AAFP)
  - Samir Shah (AAP)
  - Sharon McMullen (ACHA)
  - Cacky Tate (AIM)
  - Paul Cieslak (CSTE)
  - Jeff Goad (NFID)
  - Jessica Cataldi (PIDS)
  - Amy Middleman (SAHM)

- David Stephens (Emory)
- CDC Contributors
  - LeAnne Fox (DBD/NCIRD)
  - Susan Hariri (DBD/NCIRD)
  - Lucy McNamara (DBD/NCIRD)
  - Alison Albert (DBD/NCIRD)
  - Noele Nelson (DBD/NCIRD)
  - Jonathan Duffy (DHQP/NCEZID)
  - Tanya Myers (DHQP/NCEZID)
  - Ismael Ortega-Sanchez (DVD/NCIRD)
  - Liz Velazquez (ISD/NCIRD)
  - Jessica MacNeil (ACIP Secretariat)
- GRADE/EtR
  - Doug Campos-Outcalt (Arizona)
  - Rebecca Morgan (McMaster)

## **October ACIP Meeting Recap**

- Menveo one-vial presentation
- Introduction to the two new MenABCWY vaccines
  - Manufacturers: GSK and Pfizer
  - Policy questions
  - PICOs
  - Next steps

## **Work Group Schedule Updates**

Task	2022								2023											2024					
	6	7	8	9	10	11	12	1	2	3	4	5	6	7	8	9	10	11	12	1	2	3	4	5	6
Menveo Solution																									
Pfizer Pentavalent Vaccine																									
GSK Pentavalent Vaccine																									

## **Proposed Timeline of ACIP Presentations**

February 2023 June 2023 October 2023

- Epidemiology of meningococcal disease
- Pfizer trial data

- Pfizer GRADE, EtR, and cost study
- GSK trial data

- Pfizer vote
- GSK GRADE, EtR, and cost study

## **Summary of Recent Work Group Activities**

- GSK and Pfizer presented on their pentavalent vaccines and work group asked clarifying questions
- Work group discussed whether to reconsider adolescent immunization schedule
- Decided to postpone any reviews of the schedule until after both pentavalent vaccines have been assessed
  - Vaccine reviews will be complex and challenging
  - Need to understand epidemiology of meningococcal disease after COVID-19

## Agenda for Today

- Epidemiology of Meningococcal Disease in the United States
  - Amy Rubis, CDC
- Pfizer's MenABCWY Vaccine Clinical Trials Data
  - Pfizer Representative
- Work Group Interpretation of Pfizer's MenABCWY Vaccine Clinical Trials Data
  - Sam Crowe, CDC

For more information, contact CDC 1-800-CDC-INFO (232-4636)

TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

